Phase I Clinical Trials Underway for First MERS Treatment

(BUSINESS WIRE)-- SAB Biotherapeutics, Inc. (SAB), a leading biopharmaceutical development company, announced today that Phase I Clinical Trials are underway for its human antibody treatment (SAB-301) for MERS-CoV. The goal of the study–sponsored, funded and conducted by National Institutes of Health (NIH)–is to evaluate the dosage and safety of this new therapeutic.

Middle East Respiratory Syndrome (MERS) is a newly discovered, contagious and sometimes fatal respiratory illness, caused by a virus known as MERS coronavirus (MERS-CoV), with no known vaccines or treatments.

SAB produced SAB-301 utilizing its DiversitAb™ platform, which leverages transchromosomic cattle (Tc Bovine™). ...

Source : http://me-newswire.net//news/18464/en...